Sanofi and Earendil Labs forge $2.56bn autoimmune deal
Ahead of JP Morgan 2026, pharmaceutical giant Sanofi has inked another deal with Helixon Therapeutics-affiliated startup Earendil Labs, which will …
Post
-
-
Insilico and Servier announce $888m oncology research agreement
Insilico Medicine has entered a multi-year research and development (R&D) collaboration with Servier, worth up to $888m, to develop and …
-
Biogen’s Tysabri to be used on England’s NHS for highly active MS
The National Institute for Health and Care Excellence (NICE) has recommended natalizumab as an option for adults with highly active …
-
Samsung Bioepis initiates Byooviz commercialisation in Europe
Samsung Bioepis has started direct commercialisation of Byooviz, a biosimilar to Genentech’s Lucentis (ranibizumab), in Europe. The company has assumed commercial …
-
Valneva takes back charge of chikungunya vaccine supply in Asia
Valneva and the Serum Institute of India (SII) have ended a license agreement for chikungunya vaccine supply in Asia after …
-
China releases 2025 NRDL and first commercial insurance drug list
In early December, the 2025 updates of China’s National Reimbursement Drug List (NRDL) were finalised with a total of 114 …
-
Outlook Therapeutics receives FDA response on ONS-5010 for wet AMD
Outlook Therapeutics has received the US Food and Drug Administration’s (FDA) complete response letter (CRL) regarding the biologics licence application …
-
FDA approves Vanda Pharmaceuticals’ motion sickness drug Nereus
The US Food and Drug Administration (FDA) has approved Vanda Pharmaceuticals’ Nereus (tradipitant) for the prevention of vomiting induced by …
-
Emmaus, NIT sign Endari distribution agreement
Emmaus Life Sciences has entered into a licensing and exclusive distribution agreement with NeoImmuneTech (NIT) for Endari, a prescription-grade L-glutamine …
-
Genmab shelves Phase III lung cancer candidate
Genmab has discontinued development of acasunlimab, a bispecific antibody that was in mid and late-stage trials for solid tumours, including …
-
How one US state is tackling the drug affordability crisis
Drug affordability remains a key priority for the US government as it negotiates with pharma companies to lower individual drug …
-
Johnson & Johnson acquires Halda Therapeutics for $3.05bn
Johnson & Johnson (J&J) has completed its acquisition of Halda Therapeutics, a clinical-stage biotechnology company, for $3.05bn in cash. This move …
-
Enriched patient data needed to uncover sex differences in Alzheimer’s trials
Researchers say that women are twice as likely to develop Alzheimer’s disease as men. However, despite recent advances in treatments …
-
Sanofi buys hep B vaccine maker for $2.2bn
Sanofi has agreed to acquire hepatitis B vaccine manufacturer Dynavax for an equity value of around $2.2bn, bolstering the former's …
-
Revamping best-selling drugs to combat patent cliff has limits
As the looming patent cliff approaches, some major blockbuster drugs are set to lose their exclusivity, with pharma companies making …
